Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 28, 2020
Grant Date -
Jul 20, 2017
app pub date -
Jan 31, 2017
filing date -
May 29, 2007
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.
First Claim
Other Claims data not available
Family
International Classification(s)
- 2017 Application Filing Year
- A61K Class
- 21227 Applications Filed
- 12841 Patents Issued To-Date
- 60.50 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 5 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Oct 28, 2027 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Oct 28, 2031 |
